Lv77
3480 积分 2023-08-01 加入
PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcoma
6小时前
已关闭
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
2天前
已关闭
Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer
3天前
已完结
Role of TSC1 in physiology and diseases
1个月前
已完结
Renal cell carcinoma
2个月前
已完结
Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study
2个月前
已完结
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
2个月前
已完结
Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study
2个月前
已完结
PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma
2个月前
已完结
PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma
2个月前
已关闭
皖公网安备34019202002308
